October 11th 2024
A new AHA statement highlights the benefits of lipoprotein apheresis for familial hypercholesterolemia and urges broader access to the underutilized therapy.
October 8th 2024
Time-restricted eating, even without calorie restriction, improved glycemic control and cardiometabolic health in patients with metabolic syndrome.
October 2nd 2024
Rahul Aggarwal, MD, discusses how the VICTORION-1 PREVENT trial eligibility criteria apply to the general US population.
The HCPLive Cardiology month in review for September 2024 spotlights ESC Congress 2024, Family Heart Global Summit, pipeline updates, and more!
October 1st 2024
Elucid has received 510(k) clearance for its PlaqueIQ™ imaging analysis software to help physicians diagnose cardiovascular disease.
A Dose of Safflower Oil Each Day Might Help Keep Heart Disease at Bay
Safflower oil can improve good cholesterol, blood sugar, insulin sensitivity, and inflammation in obese postmenopausal women who have Type 2 diabetes.
A Review of the Causes of Secondary Hypertension
Dr. Pullen discusses the diagnosis of various forms of hypertension, the most common chronic health problem seen by many family physicians.
Uncontrolled Hypertension and Cholesterol Still a Problem in the US
Although one in three American adults has hypertension, fewer than half of patients with this condition have it under control.
Link Between Lupus and Atherosclerotic Diseases Discovered
Researchers in China have demonstrated interferon-alpha is associated with increased risk of atherosclerosis in patients with systemic lupus erythematosus.
Being Healthy Is Not Just the Absence of Disease
The health and economic costs of poor lifestyle choices, poor health care planning, and misaligned incentives for care are the themes this week.
The Relationship between Stenosis Severity and Ischemia
Podcast discussion of the value of CT angiography to measure stenosis severity and predict ischemia.
Should We Rethink the Use of Statins in Patients at Low Risk for CVD?
A review of multiple trials found that there is little evidence to support the use of statins to prevent Cardiovascular disease in low-risk patients.
Diabetes and Heart Disease
Two experts discuss diabetes and cardiovascular disease risk.
Strategies for Treating High Blood Pressure and High Cholesterol
Video explores current options for managing hypertension and atherosclerosis.
Top Advances in Cardiovascular Research from 2010
The American Heart Association recently revealed its annual list of the most important cardiovascular and stroke research findings from the past year.
Patients with Psoriasis at Risk for Metabolic Syndrome
Data from the National Health and Nutrition Examination Survey show a doubling in the prevalence of the metabolic syndrome among patients with psoriasis.
Osteoporosis Friends with Atherosclerosis, Despite Parental Admonishment
Norwegian researchers believe that osteoprotegerin may be the common denominator linking low bone density and atherosclerotic changes.
Another Round of Drinks, Bartender...but Only One
Moderate drinking, as in one to 13 drinks per week, lowers a person's risk of developing characteristics associated with metabolic syndrome.
What Is the Cause of Increased Heart Attack Risk in African Americans?
African Americans may have increased levels of non-calcified plaque, which is more vulnerable to rupturing and is difficult to detect with CT scans.
ASN 2010: Lowering LDL in CKD Patients Reduces Risk of CV Events
SHARP trial shows that combination statin therapy in patients with CKD reduces risk of heart attack and stroke without raising cancer risk.
AHA 2010: Study Results Show Statins Do Not Increase Cancer Risk
Retrospective analysis reveals that statin use is not associated with increased risk of cancer.
AHA 2010: PTSD Linked to Increased Risk of CVD, Death in Veterans
Post-traumatic stress disorder more than doubles a veteran's risk of death from any cause and is an independent risk factor for cardiovascular disease.
AHA 2010: CETP-inhibitor Anacetrapib has Dramatic Effects on HDL, LDL
Study shows that cholesteryl ester transfer protein (CETP) inhibitor anacetrapib reduced LDL by 40% and doubled HDL in patients with coronary disease.
AHA 2010: Options for Lowering LDL-C in the Statin-intolerant Patient
Once you've determined that a patient truly is statin-intolerant, there are several viable alternatives for lipid-lowering therapy, including niacin.
ACR 2010: Tocilizumab Has Beneficial Lipid Effect in Patients with RA
Drug elevates lipid particles that are thought to be protective, leaves proatherogenic particles unchanged, and reduces markers of inflammation.
ACR 2010: More on the Use of Statins in Children and Adolescents with Lupus
Bonus coverage of study results announced at ACR/ARHP 2010 showing the effects of statins on cardiovascular disease risk in children with lupus.
ACR 2010: Statins Not Routinely Indicated for Children with Lupus
Studies show that statins should not be routinely prescribed in children and adolescents with lupus despite their increased risk of atherosclerosis.
ACR 2010: Inflammation Associated with Arthritis May Worsen Atherosclerosis
Systemic inflammation and rheumatoid arthritis disease activity may contribute to the progression of atherosclerosis.
Atherosclerosis: Patient-education Videos
These videos help explain atherosclerosis and illustrate the process of plaque formation and the effects this can have on cardiovascular health.
Controversies in New Treatment Measures for Metabolic Syndrome
Should measures of lipoprotein levels and LDL particle size be taken into account when treating cardiometabolic issues?
The Great Debate: Niacin vs. Fibrate Part 2
Allen Taylor, MD, explained the benefits of using niacin in the treatment of high cholesterol during a debate at the Cardiometabolic Health Congress.
The Role of HDL in Healthy Lipid Function: Research Updates
At the Cardiometabolic Health Congress, Daniel Rader, MD, explained why raising HDL cholesterol may be pivotal to improving cardiovascular health.
7-Point Prevention Rx for Patients at Risk for CVD and Hyperlipidemia
The goal when evaluating patients for CVD risk is to know what signs to look for and to devise an evidence-based, individualized treatment plan.
Widely Used Web Tool Miscalculates Heart Attack Risk
If you can't trust a heart attack risk assessment that can be done with a few clicks of the mouse, what can you trust?
Plavix to Follow Lipitor as a Generic Blockbuster
Plavix will soon follow Lipitor and go off patent, opening the door for a generic alternative for cardiovascular disease and stroke patients.